[go: up one dir, main page]

AR059089A1 - Administracion intraventricular de una enzima para enfermedades de almacenamiento lisosomal - Google Patents

Administracion intraventricular de una enzima para enfermedades de almacenamiento lisosomal

Info

Publication number
AR059089A1
AR059089A1 ARP070100239A ARP070100239A AR059089A1 AR 059089 A1 AR059089 A1 AR 059089A1 AR P070100239 A ARP070100239 A AR P070100239A AR P070100239 A ARP070100239 A AR P070100239A AR 059089 A1 AR059089 A1 AR 059089A1
Authority
AR
Argentina
Prior art keywords
storage diseases
enzyme
lisosomal
intraventricular administration
lysosomal storage
Prior art date
Application number
ARP070100239A
Other languages
English (en)
Inventor
James Dodge
Marco A Passini
Lamya Shihabuddin
Seng H Cheng
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of AR059089A1 publication Critical patent/AR059089A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/04—Phosphoric diester hydrolases (3.1.4)
    • C12Y301/04012—Sphingomyelin phosphodiesterase (3.1.4.12)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/06—Sulfuric ester hydrolases (3.1.6)
    • C12Y301/06013—Iduronate-2-sulfatase (3.1.6.13)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/0102—Alpha-glucosidase (3.2.1.20)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01045—Glucosylceramidase (3.2.1.45), i.e. beta-glucocerebrosidase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01076—L-Iduronidase (3.2.1.76)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/14—Dipeptidyl-peptidases and tripeptidyl-peptidases (3.4.14)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)

Abstract

Enfermedades de almacenamiento lisosomal pueden tratarse exitosamente mediante la aplicacion intraventricular de la enzima etiologicamente deficiente en la enfermedad. Para lograr el efecto máximo, la administracion puede realizarse lentamente. Sorprendentemente, se observan efectos en ambos lados de la barrera sangre-cerebro, por lo cual éste es un medio de aplicacion ideal para enfermedades de almacenamiento lisosomal que afectan ambos, el cerebro y organos viscerales.
ARP070100239A 2006-01-20 2007-01-19 Administracion intraventricular de una enzima para enfermedades de almacenamiento lisosomal AR059089A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US76037806P 2006-01-20 2006-01-20

Publications (1)

Publication Number Publication Date
AR059089A1 true AR059089A1 (es) 2008-03-12

Family

ID=38288294

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP070100239A AR059089A1 (es) 2006-01-20 2007-01-19 Administracion intraventricular de una enzima para enfermedades de almacenamiento lisosomal
ARP170102114A AR109170A2 (es) 2006-01-20 2017-07-27 Esfingomielinasa ácida para uso en la prevención o el tratamiento de la enfermedad de niemann-pick a o b en un paciente

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP170102114A AR109170A2 (es) 2006-01-20 2017-07-27 Esfingomielinasa ácida para uso en la prevención o el tratamiento de la enfermedad de niemann-pick a o b en un paciente

Country Status (19)

Country Link
US (4) US8926967B2 (es)
EP (3) EP3517124A1 (es)
JP (1) JP5681345B2 (es)
CN (1) CN101431960A (es)
AR (2) AR059089A1 (es)
BR (1) BRPI0706699A2 (es)
CA (2) CA2636991C (es)
DK (2) DK1984018T3 (es)
ES (2) ES2716206T3 (es)
HU (1) HUE041840T2 (es)
IL (2) IL192740A (es)
LT (1) LT2666476T (es)
MX (1) MX349749B (es)
PL (2) PL2666476T3 (es)
PT (2) PT1984018E (es)
RU (3) RU2529830C2 (es)
SI (2) SI2666476T1 (es)
TR (1) TR201903855T4 (es)
WO (1) WO2007084737A2 (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR059089A1 (es) 2006-01-20 2008-03-12 Genzyme Corp Administracion intraventricular de una enzima para enfermedades de almacenamiento lisosomal
CA2641359C (en) * 2006-02-09 2022-10-04 Genzyme Corporation Slow intraventricular delivery
PT2154969E (pt) 2007-05-16 2016-02-17 Brigham & Womens Hospital Tratamento das sinucleinopatias
ES2735023T3 (es) 2008-12-16 2019-12-13 Genzyme Corp Intermedios sintéticos para preparar conjugados de oligosacáridos-proteínas
CN102459611B (zh) 2009-05-02 2016-11-09 建新公司 神经退行性疾病的基因治疗
FI3998078T3 (fi) * 2009-08-28 2025-12-04 Icahn School Med Mount Sinai Annoksensuurentamisentsyymikorvaushoito happaman sfingomyelinaasin puutoksen hoitamista varten
MX338426B (es) 2010-04-23 2016-04-15 Synageva Biopharma Corp Enzima de enfermedad del almacenamiento lisosomico.
RU2012154576A (ru) * 2010-06-25 2014-07-27 Шир Хьюман Дженетик Терапис, Инк. Способы и композиции для доставки к цнс гепаран-n-сульфатазы
DK2588130T3 (en) 2010-06-25 2016-10-24 Shire Human Genetic Therapies Cns delivery of therapeutic agents
KR102318997B1 (ko) * 2010-06-25 2021-10-29 샤이어 휴먼 지네틱 테라피즈 인크. 아릴설파타제 a의 cns 전달을 위한 방법들 및 조성물들
EP2588132A4 (en) * 2010-06-25 2014-10-15 Shire Human Genetic Therapies METHOD AND COMPOSITIONS FOR DELIVERING BETA GALACTOCEREBROSIDASE INTO THE CNS
NZ605863A (en) 2010-06-25 2015-02-27 Shire Human Genetic Therapies Methods and compositions for cns delivery of iduronate-2-sulfatase
HRP20211520T1 (hr) 2010-06-25 2021-12-24 Shire Human Genetic Therapies, Inc. Postupci i pripravci za dostavu iduronat-2-sulfataze u središnji živčani sustav
JP2012062312A (ja) * 2010-08-19 2012-03-29 Yoshikatsu Eto ハンター症候群の治療剤
PL2613798T5 (pl) 2010-09-09 2018-06-29 Synageva Biopharma Corp. Zastosowanie lizosomalnej kwaśnej lipazy do leczenia niedoboru lizosomalnej kwaśnej lipazy u pacjentów
US9387236B2 (en) * 2011-06-10 2016-07-12 Prothera Inc. Pharmaceutical compositions containing protease and methods for the treatment of lysosomal storage diseases
EP2793922B1 (en) 2011-12-23 2019-10-30 Shire Human Genetic Therapies, Inc. Stable formulations for cns delivery of arylsulfatase a
AU2012358223B2 (en) * 2011-12-23 2018-01-18 Takeda Pharmaceutical Company Limited Treatment of cognitive impairment of Hunter syndrome by intrathecal delivery of iduronate-2-sulfatase
EA039246B1 (ru) * 2012-12-06 2021-12-22 Шир Хьюман Дженетик Терапис, Инк. Способ лечения когнитивных нарушений, связанных с синдромом хантера
CA2901978A1 (en) 2013-02-20 2014-08-28 Valerion Therapeutics, Llc Methods and compositions for treatment of pompe disease
IL284102B2 (en) * 2013-06-07 2023-04-01 Genzyme Corp Marker for acid sphingomyelinase disorders and uses thereof
JP6616189B2 (ja) 2013-12-25 2019-12-04 Ｊｃｒファーマ株式会社 血液脳関門を通過する新規抗トランスフェリン受容体抗体
AU2015214358A1 (en) 2014-02-04 2016-08-18 New York University Progranulin (PGRN) and its derivatives for diagnosis and treatment of lysosomal storage diseases
GB201508025D0 (en) 2015-05-11 2015-06-24 Ucl Business Plc Fabry disease gene therapy
HK1247933A1 (en) 2015-06-24 2018-10-05 Jcr Pharmaceuticals Co., Ltd. Fusion protein containing bdnf
CN114409783B (zh) 2015-06-24 2025-09-16 Jcr制药股份有限公司 通过血脑屏障的抗人转铁蛋白受体抗体
WO2017024137A1 (en) * 2015-08-04 2017-02-09 New York University Progranulin (pgrn) fragments and derivatives for treatment or alleviation of lysosomal storage diseases
RU2634113C1 (ru) * 2016-11-18 2017-10-24 Государственное бюджетное учреждение "Академия наук Республики Саха (Якутия)" (ГБУ АН РС(Я)) Способ фиксации головного мозга ископаемого позднеплейстоценового млекопитающего
CN110100000B (zh) 2016-12-26 2023-06-20 Jcr制药股份有限公司 含有bdnf的融合蛋白
WO2018124121A1 (ja) 2016-12-26 2018-07-05 Ｊｃｒファーマ株式会社 血液脳関門を通過する新規な抗ヒトトランスフェリン受容体抗体
US20200277584A1 (en) 2017-10-02 2020-09-03 Denali Therapeutics Inc. Fusion proteins comprising enzyme replacement therapy enzymes
UY38238A (es) * 2018-05-25 2019-12-31 Genzyme Corp Composiciones farmacéuticas para el tratamiento de la deficiencia de esfingomielinasa ácida
US20220125892A1 (en) 2019-02-01 2022-04-28 OXYRANE UK Ltd. Glucocerebrosidase polypeptides
RU2723187C1 (ru) * 2019-10-04 2020-06-09 федеральное государственное автономное образовательное учреждение высшего образования "Казанский (Приволжский) федеральный университет" (ФГАОУ ВО КФУ) Генетическая кассета, содержащая кодон-оптимизированные нуклеотидные последовательности генов HEXA и HEXВ, и фармацевтическая композиция для лечения болезни Тея-Сакса
WO2022165421A1 (en) * 2021-02-01 2022-08-04 The Trustees Of The University Of Pennsylvania Compositions and methods for treatment of niemann pick type a disease

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8303626D0 (sv) 1983-06-23 1983-06-23 Kabigen Ab A recombinant plasmid a transformant microorganism, a polydoxyrebonucleotide segment, a process for producing a biologically active protein, and the protein thus produced
US5670488A (en) 1992-12-03 1997-09-23 Genzyme Corporation Adenovirus vector for gene therapy
US5919676A (en) 1993-06-24 1999-07-06 Advec, Inc. Adenoviral vector system comprising Cre-loxP recombination
AU7676894A (en) 1993-08-27 1995-03-21 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Convection-enhanced drug delivery
WO1995029993A1 (en) 1994-04-28 1995-11-09 The University Of Michigan Gene delivery vector using plasmid dna packaged into an adenovirus and a packaging cell line
EP0821739B1 (en) 1995-04-17 2003-06-18 The Board Of Regents, The University Of Texas System An adenovirus helper-virus system
ATE278794T1 (de) 1995-06-15 2004-10-15 Crucell Holland Bv Verpackungssysteme für humane, menschliche adenoviren, zur verwendung in die gentherapie
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
NZ330553A (en) 1996-01-05 2001-04-27 Genetic Therapy Inc Recombinase-mediated generation of adenoviral vectors where all adenoviral genes of all regions E1 to E4 and L1 to L5 of the adenoviral genome are eliminated
US5735814A (en) * 1996-04-30 1998-04-07 Medtronic, Inc. Techniques of treating neurodegenerative disorders by brain infusion
EP2327775A3 (en) * 1996-09-13 2012-10-24 Shire Human Genetic Therapies, Inc. Therapy for alpha-galactosidase a deficiency
US7033598B2 (en) 1996-11-19 2006-04-25 Intrabrain International N.V. Methods and apparatus for enhanced and controlled delivery of a biologically active agent into the central nervous system of a mammal
US6042579A (en) * 1997-04-30 2000-03-28 Medtronic, Inc. Techniques for treating neurodegenerative disorders by infusion of nerve growth factors into the brain
US5994136A (en) 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
WO1999057296A1 (en) 1998-05-01 1999-11-11 Genzyme Corporation Partially deleted adenoviral vectors
US20060014166A1 (en) 2004-01-27 2006-01-19 Yossi Cohen Novel nucleotide and amino acid sequences, and assays and methods of use thereof for diagnosis of endometriosis
US6702945B2 (en) 2000-12-28 2004-03-09 Exxonmobil Research And Engineering Company Ionic membranes for organic sulfur separation from liquid hydrocarbon solutions
US6689756B2 (en) 2001-03-02 2004-02-10 Integra Lifesciences Corporation Treatment of neurological disease
AU2002357805A1 (en) 2001-12-07 2003-06-23 Neuron Therapeutics Protection of neurological tissue by direct cns perfusion cooling
AU2003298749A1 (en) 2002-11-26 2004-06-18 Seacoast Neuroscience, Inc. Buoyant polymer particles delivering therapeutic agents
CA2518407A1 (en) 2003-03-12 2004-09-23 Samaritan Pharmaceuticals, Inc. Animal model simulating neurologic disease
US20040258666A1 (en) * 2003-05-01 2004-12-23 Passini Marco A. Gene therapy for neurometabolic disorders
JP5624256B2 (ja) 2003-06-20 2014-11-12 ラプター・ファーマシューティカル・インコーポレイテッド 脳および他の組織への治療化合物の送達
US20050026823A1 (en) 2003-06-20 2005-02-03 Biomarin Pharmaceutical Inc. Use of the chaperone receptor-associated protein (RAP) for the delivery of therapeutic compounds to the brain and other tissues
US7442372B2 (en) 2003-08-29 2008-10-28 Biomarin Pharmaceutical Inc. Delivery of therapeutic compounds to the brain and other tissues
US20050208090A1 (en) * 2004-03-18 2005-09-22 Medtronic, Inc. Methods and systems for treatment of neurological diseases of the central nervous system
US20080233655A1 (en) 2004-03-31 2008-09-25 Children, Youth And Women's Health Service Screening For Lysosomal Storage Disease Status
WO2005099748A1 (de) * 2004-04-13 2005-10-27 Cilian Ag Rekombinante lysosomale enzyme mit ciliaten-typischem glykosylierungsmuster für die therapie
US8889127B2 (en) * 2004-07-01 2014-11-18 Icahn School Of Medicine At Mount Sinai Targeted protein replacement for the treatment of lysosomal storage disorders
AR059089A1 (es) 2006-01-20 2008-03-12 Genzyme Corp Administracion intraventricular de una enzima para enfermedades de almacenamiento lisosomal
AR059088A1 (es) 2006-01-20 2008-03-12 Genzyme Corp Administracion intraventricular de una proteina para esclerosis lateral amiotrofica
CA2641359C (en) * 2006-02-09 2022-10-04 Genzyme Corporation Slow intraventricular delivery
SI2158322T1 (sl) * 2007-06-06 2017-10-30 Genzyme Corporation Genska terapija za bolezni lizosomskega shranjevanja

Also Published As

Publication number Publication date
CA2636991A1 (en) 2007-07-26
AR109170A2 (es) 2018-11-07
RU2529830C2 (ru) 2014-09-27
US8926967B2 (en) 2015-01-06
RU2014129319A (ru) 2016-02-10
PT2666476T (pt) 2019-03-28
US10080783B2 (en) 2018-09-25
EP2666476B1 (en) 2018-12-19
LT2666476T (lt) 2019-04-10
IL192740A0 (en) 2009-02-11
EP1984018A2 (en) 2008-10-29
EP2666476A1 (en) 2013-11-27
DK2666476T3 (en) 2019-04-08
SI1984018T1 (sl) 2014-11-28
PL2666476T3 (pl) 2019-06-28
US20210228692A1 (en) 2021-07-29
EP1984018B1 (en) 2014-10-01
WO2007084737A3 (en) 2008-10-23
BRPI0706699A2 (pt) 2011-04-05
PT1984018E (pt) 2014-10-22
CA2636991C (en) 2017-07-04
WO2007084737A2 (en) 2007-07-26
HUE041840T2 (hu) 2019-05-28
PL1984018T3 (pl) 2015-04-30
TR201903855T4 (tr) 2019-04-22
US20190083582A1 (en) 2019-03-21
IL250937A0 (en) 2017-04-30
EP1984018A4 (en) 2010-07-21
ES2716206T3 (es) 2019-06-11
US20150313970A1 (en) 2015-11-05
DK1984018T3 (da) 2014-11-03
MX349749B (es) 2017-08-10
IL192740A (en) 2017-11-30
JP5681345B2 (ja) 2015-03-04
US20090130079A1 (en) 2009-05-21
RU2008134120A (ru) 2010-02-27
CN101431960A (zh) 2009-05-13
RU2665381C2 (ru) 2018-08-29
ES2526710T3 (es) 2015-01-14
JP2009525963A (ja) 2009-07-16
SI2666476T1 (sl) 2019-04-30
CA2966155A1 (en) 2007-07-26
RU2018129747A (ru) 2020-02-19
EP3517124A1 (en) 2019-07-31

Similar Documents

Publication Publication Date Title
AR059089A1 (es) Administracion intraventricular de una enzima para enfermedades de almacenamiento lisosomal
TW200745124A (en) Azepinoindole derivatives as pharmaceutical agents
WO2006012642A3 (en) Pyrrole derivatives as pharmaceutical agents
BR112012006283A2 (pt) formulação de adamts13 estabilizada, método para fabricar uma formulação de adamts13 estabilizada, kit, e métodos para tratar ou prevenir uma doença e para tratar ou previnir um enfarte
CL2009000402A1 (es) Compuestos derivados de 2-amino-acetamida sustituida; composicion farmaceutica; utiles en el tratamiento de enfermedades pulmonares, enfermedad reumatica, enfermedad autoinmune, entre otras.
WO2008022349A3 (en) Agents for blood-brain barrier delivery
MX2009006651A (es) Antagonistas de activina-actrii y usos para incrementar los niveles de globulos rojo.
WO2010059253A3 (en) Methods and compositions for localized agent delivery
EA201101523A1 (ru) Способы лечения метаболических нарушений, использующие эпиметаболические переключатели, многоаспектные внутриклеточные молекулы или факторы влияния
EA201001329A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
WO2008003007A3 (en) Compositions and methods for treating parasitic infections
EA201071059A1 (ru) Способы и композиции для лечения воспаления и связанных с воспалением патологических состояний
BR122020010601B8 (pt) conjugados de proteína-oligossacarídeo, seus usos, e composições farmacêuticas
EA201001332A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
BRPI0712607A8 (pt) métodos de tratamento de acidente vascular cerebral
GT201200138A (es) Derivados de sulfonamida heterocíclicos útiles como inhibidores de mek
WO2009135178A3 (en) Methods for production and use of substance-loaded erythrocytes (s-les) for observation and treatment of microvascular hemodynamics
WO2010097788A3 (en) Visfatin therapeutic agents for the treatment of acne and other conditions
WO2009149106A3 (en) Microparticles for the treatment of disease
CL2009000727A1 (es) Compuestos derivados de n-hidroxi-3-fenilprop-2-enemida y n-hidroxi-3-fenilpropanamida sustituidos; inhibidores de la enzima desacetilasa; su composicion farmaceutica; utiles en el tratamiento del cancer, tumores, psoriasis, alzheimer, entre otras.
EA200970483A1 (ru) Применение пролекарств габапентина и прегабалина для лечения шума в ушах
ITMI20080570A1 (it) Procedimento per la preparazione di polibutadiene ramificato ad alto contenuto in unita' 1,4-cis
WO2007105015A3 (en) DERIVATIVES OF 18ß-GLYCYRRHETINIC ACID
CY1116831T1 (el) ΧΡΗΣΗ 24-norUDCA
GT200600115A (es) Metodo para identificar blancos terapeuticos para el tratamiento de atrofia vulvoginal

Legal Events

Date Code Title Description
FC Refusal